Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled
BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) Phase 2 part 2 of the potentially registrational study is being initiated; anticipate first patient dosed this quarter
BA3071 Phase 1 study ongoing with first two dose escalation cohorts completed; third cohort (70mg) on-going
CAB clinical programs continue to progress with multiple significant inflection points expected in 2023
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.